Retraction notice to " HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells" [eBioMedicine 48 (2019) 117 - 129].
作者信息
Yao Lili, Zhou Yadi, Sui Zhenhua, Zhang Yanling, Liu Yankun, Xie Hong, Gao Huijie, Fan Hongxia, Zhang Yi, Liu Min, Li Shengping, Tang Hua
机构信息
Tianjin Life Science Research Center, Tianjin Laboratory of Inflammation Biology, Collaborative Innovation Center of Tianjin for Medical Epigenetics, Department of Pathogen Biology, Basic Medical School, Tianjin Medical University, Tianjin 300070, China.
The Cancer Institute, Tangshan People's Hospital, Tangshan 063001, China.
出版信息
EBioMedicine. 2021 Oct;72:103667. doi: 10.1016/j.ebiom.2021.103667.
Abstract
摘要
相似文献
1
Retraction notice to " HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells" [eBioMedicine 48 (2019) 117 - 129].撤回声明：“HBV编码的miR-2通过下调TRIM35但上调RAN在肝癌细胞中发挥癌基因作用”[《电子生物医学》48卷（2019年）第117 - 129页]
EBioMedicine. 2021 Oct;72:103667. doi: 10.1016/j.ebiom.2021.103667.
2
RETRACTED: HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells.撤回：HBV 编码的 miR-2 通过下调 TRIM35 但上调 RAN 在肝癌细胞中发挥癌基因作用。
EBioMedicine. 2019 Oct;48:117-129. doi: 10.1016/j.ebiom.2019.09.012. Epub 2019 Sep 14.
3
Retraction notice to 'The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells' [EBioMedicine 35 (2018) 204-221].撤回通知：“miR 495 - UBE2C - ABCG2/ERCC1轴通过下调顺铂耐药非小细胞肺癌细胞中的耐药基因逆转顺铂耐药性”[《电子生物医学》35 (2018) 204 - 221]
EBioMedicine. 2021 Jan;63:103168. doi: 10.1016/j.ebiom.2020.103168.
4
miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.微小RNA-4417靶向含三联基序蛋白35（TRIM35）并调节丙酮酸激酶M2型（PKM2）磷酸化，以促进肝癌细胞增殖并抑制其凋亡。
Med Sci Monit. 2017 Apr 10;23:1741-1750. doi: 10.12659/msm.900296.
5
Retraction notice to "Corrigendum to 'MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway' [EBioMedicine 46 (2019) 66-78]" [EBioMedicine 55 (2020) 102772].撤回声明：“《对〈MicroRNA-134通过PLXNA1介导的MAPK信号通路预防食管鳞状细胞癌进展〉的勘误》[《E生物医学》46 (2019) 66 - 78]”[《E生物医学》55 (2020) 102772]
EBioMedicine. 2024 May;103:105106. doi: 10.1016/j.ebiom.2024.105106. Epub 2024 Apr 4.
6
Retraction notice to 'Neurotensin contributes to pediatric intestinal failure-associated liver disease via regulating intestinal bile acids uptake': [EBioMedicine 35 (2018) 133-141].撤回关于“神经降压素通过调节肠道胆汁酸摄取促进小儿肠衰竭相关肝病”的通知：[《转化医学杂志》35卷（2018年）第133 - 141页]
EBioMedicine. 2020 Jul;57:102927. doi: 10.1016/j.ebiom.2020.102927.
7
Retraction notice to "LSAMP-AS1 binds to microRNA-183-5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN" [eBioMedicine 50 (2019) 178 - 190].撤回通知：“LSAMP-AS1通过上调肿瘤抑制因子DCN与微小RNA-183-5p结合以抑制前列腺癌进展”[《电子生物医学》50 (2019) 178 - 190]
EBioMedicine. 2021 Oct;72:103665. doi: 10.1016/j.ebiom.2021.103665.
8
Retraction notice to "LINC00184 silencing inhibits glycolysis and restores mitochondrial oxidative phosphorylation in esophageal cancer through demethylation of PTEN" [EBioMedicine 44 (2019) 298-310].撤回通知：“LINC00184沉默通过PTEN去甲基化抑制食管癌糖酵解并恢复线粒体氧化磷酸化”[《电子生物医学》44卷（2019年）第298 - 310页]
EBioMedicine. 2024 Jun;104:105192. doi: 10.1016/j.ebiom.2024.105192. Epub 2024 Jun 3.
9
Hepatitis B virus regulates apoptosis and tumorigenesis through the microRNA-15a-Smad7-transforming growth factor beta pathway.乙型肝炎病毒通过微小RNA-15a-Smad7-转化生长因子β途径调节细胞凋亡和肿瘤发生。
J Virol. 2015 Mar;89(5):2739-49. doi: 10.1128/JVI.02784-14. Epub 2014 Dec 24.
10
Retraction notice to 'The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC' [EBioMedicine 37 (2018) 188-204].撤回声明：“抗肿瘤药物二甲双胍通过干扰IRF-1与非小细胞肺癌中YAP启动子的结合来下调YAP”[《电子生物医学》37卷（2018年）第188 - 204页]
EBioMedicine. 2021 Jan;63:103169. doi: 10.1016/j.ebiom.2020.103169.
Zotero 插件